Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Factors influencing the prognosis for occupational hand eczema - new trends: new trends

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparing apples, oranges and atopic dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Optimal sunscreen use, during a sun holiday with a very high ultraviolet index, allows vitamin D synthesis without sunburn

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

    Research output: Contribution to journalJournal articleResearchpeer-review

  • HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC)
View graph of relations

BACKGROUND: There is no consensus on core outcome domains for hidradenitis suppurativa (HS). Heterogeneous outcome measure instruments in clinical trials likely leads to outcome-reporting bias and limits the ability to synthesize evidence.

OBJECTIVES: To achieve global multistakeholder consensus on a core outcome set (COS) of domains regarding what to measure in clinical trials for HS.

METHODS: Six stakeholder groups participated in a Delphi process that included five anonymous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS. The aim was for a 1 : 1 ratio of patients to healthcare professionals (HCPs).

RESULTS: A total of 41 patients and 52 HCPs from 19 countries in four continents participated in the consensus process, which yielded a final COS that included five domains: pain, physical signs, HS-specific quality of life, global assessment and progression of course. A sixth domain, symptoms, was highly supported by patients and not by HCPs but is recommended for the core domain set.

CONCLUSIONS: Routine adoption of the COS in future HS trials should ensure that core outcomes of importance to both patients and HCPs are collected.

Original languageEnglish
JournalBritish Journal of Dermatology
Volume179
Issue number3
Pages (from-to)642-650
Number of pages9
ISSN0007-0963
DOIs
Publication statusPublished - Sep 2018

ID: 56061941